论文部分内容阅读
一项高血压患者的研究结果表明,与常用的基于β阻滞剂的抗高血压疗法相比,基于钙通道阻滞剂氨氯地平(amlodipine)的高血压疗法已被证实可使高血压人群新发糖尿病的几率减少34%;该项研究是欧洲有史以来规模最大的针对高血压患者的研究,涉及近两万名患者。研究结果近日在西班牙巴塞罗那举行的世界心脏病学大会上发表。英裔斯堪的纳维亚人心脏结果试验(ASCOT)对β-阻滞剂阿替洛尔(atenolol)单一制剂或联用利尿剂苄氟噻嗪(bendroflumethiazide)以及钙通道阻滞剂氨氯地平单一制剂或联用血管紧张素转换酶(ACE)抑制剂培哚普利(perindopril)两种高血压控制疗法进行了比较;共计19257名患者参与该项研究,其中14120人开始时并未患糖尿病,而1366人在研究期间发生糖尿病,氨氯地平组567例(8%),阿替洛尔组799例(11.4%)。
A study of patients with hypertension found that amlodipine-based hypertensive therapy, a calcium channel blocker, has been shown to increase blood pressure in hypertensive subjects compared with commonly used beta-blocker-based antihypertensives The risk of new diabetes is reduced by 34%; the study is the largest study of hypertension in Europe ever since, involving nearly 20,000 patients. The findings were presented at the World Congress of Cardiology at Barcelona, Spain recently. English Scandinavian Heart Results Trial (ASCOT) A beta-blocker atenolol single agent or bendroflumethiazide plus calcium channel blocker Ammonia Comparison of two single-agent formulations of topotecan alone or in combination with ACE inhibitors perindopril for hypertension control; a total of 19257 patients participated in the study, of whom 14,120 did not initially develop atrial fibrillation Diabetes mellitus, while 1366 people developed diabetes during the study, 567 (8%) with amlodipine and 799 (11.4%) with atenolol.